Inhibikase Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
Inhibikase Therapeutics (Nasdaq: IKT) reported its Q1 2022 financial results, revealing a net loss of $4.7 million, or $0.18 per share, up from a loss of $2.6 million, or $0.26 per share, in Q1 2021. R&D expenses rose to $3.0 million, primarily due to Phase I clinical trial expenditures. Cash and cash equivalents were $36.6 million, sufficient to fund operations into Q3 2023. The company anticipates initiating its Phase 2a study for IkT-148009 in Parkinson's disease and submitting an IND for IkT-001Pro for Chronic Myelogenous Leukemia this quarter.
- Anticipation of dosing first patients in Phase 2a study for IkT-148009 in Q2 2022.
- Sufficient cash of $36.6 million to fund operations into Q3 2023.
- Expected submission of IND application for IkT-001Pro in Q2 2022.
- Increased net loss to $4.7 million in Q1 2022 compared to $2.6 million in Q1 2021.
- R&D expenses increased to $3.0 million in Q1 2022 from $2.4 million in Q1 2021.
Company to host conference call and webcast on Tuesday, May 17, 2022, at 8:00am ET
BOSTON and ATLANTA, May 16, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today reported financial results for the first quarter ended March 31, 2022 and highlighted recent developments.
"As we kicked off 2022, we have worked diligently to advance our clinical and preclinical programs as well as extend our thought leadership in Parkinson's disease. This past month we brought together leading key opinion leaders in the field of movement disorders to host an educational event highlighting the current unmet need, competitive and regulatory landscape in Parkinson's disease as well as delineated our development strategy for IkT-148009 as a potential therapeutic option for patients," commented Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase. "As we look ahead, we anticipate dosing the first patients in our Phase 2a study for IkT-148009 in Parkinson's disease this quarter. This study will allow us to evaluate our selective c-Abl kinase inhibitor in Parkinson's patients dosed for a 12-week period. In addition, we anticipate submitting our IND application for IkT-001Pro for stable phase Chronic Myelogenous Leukemia as well as report preclinical data from at least one study of IkT-148009 in Multiple Systems Atrophy in the second quarter. As we advance these programs forward, we will continue to be good stewards of capital to maximize shareholder value. We expect our current cash on hand to be sufficient to fund our operations into the third quarter of 2023."
- Phase 2a clinical study for IkT-148009: Inhibikase anticipates dosing the first patients in its Phase 2a study of IkT-148009, known as the "201 Trial," in the second quarter. The trial will be a 3:1 randomized, double-blind, twelve-week dosing trial and will evaluate the safety and tolerability of three doses of IkT-148009 in up to 120 patients diagnosed with Parkinson's disease who have not yet progressed to the need for symptomatic therapy. The trial will also measure a hierarchy of motor and non-motor function inside and outside of the brain as secondary endpoints and will evaluate whether treatment with IkT-148009 leads to a reduction or clearance of pathogenic alpha-synuclein aggregates as exploratory endpoints.
- Hosted virtual investor event featuring Key Opinion Leaders in Parkinson's disease: In April 2022, Inhibikase held a virtual investor event highlighting the Company's clinical progress of IkT-148009, provided an overview of the current Phase 2 program and described the current unmet need and competitive landscape in Parkinson's disease. A replay of the event can be accessed here.
- Phase 1b study in clinical trial of IkT-148009: In March 2022, Inhibikase presented data from the first cohort of its Phase 1b study for IkT-148009 at the Alzheimer's & Parkinson's Diseases Conference (AD/PD™). Data suggested that the safety and tolerability profile in patients closely matched that of older healthy volunteers. Pharmacokinetics of IkT-148009 in volunteers and subjects was also similar, further suggesting that the pharmacology of IkT-148009 is consistent across patient groups and penetrates the Central Nervous System. The Company expects to complete dosing of the second cohort of the Phase 1b study in the second quarter of 2022 and present additional data at a medical meeting later this year.
- Investigational New Drug application (IND) for IkT-001Pro for stable-phase Chronic Myelogenous Leukemia (CML): In the first quarter of 2022, Inhibikase completed clinical batch manufacturing of its pill formulated IkT-001Pro, a prodrug formulation of imatinib mesylate. The Company is conducting the necessary stability studies for the IND submission package and expects to submit the IND application in the second quarter of 2022. Following clearance by the FDA, the Company expects to initiate bioequivalence studies in accordance with the 505(b)(2) regulatory pathway.
- Preclinical studies evaluating IkT-148009 in animal models of Multiple System Atrophy (MSA): Inhibikase expects to report preclinical data evaluating IkT-148009 in at least one of two animal models of MSA in the second quarter of 2022. Depending on the preclinical results in animal models of MSA and subject to agreement with the FDA and equivalent regulatory bodies in the European Union, Inhibikase may advance IkT-148009 into a Phase 2a clinical study in the fourth quarter of 2022.
Net Loss: Net loss for the quarter ended March 31, 2022, was
R&D Expenses: Research and development expenses were
SG&A Expenses Selling, general and administrative expenses for the quarter ended March 31, 2022 were
Cash Position: Cash and cash equivalents were
The conference call is scheduled to begin at 8:00am ET Tuesday, May 17, 2022. Participants should dial 877-407-4018 (United States) or 201-689-8471 (International) with the conference code 13729218. A live webcast may be accessed using the link here, or by visiting the investors section of the Company's website at www.inhibikase.com. After the live webcast, the event will be archived on Inhibikase's website for approximately 90 days after the call.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2021, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts:
Company Contact:
Milton H. Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com
Inhibikase Therapeutics, Inc. | ||||||||
Consolidated Balance Sheets | ||||||||
March 31, | December 31, | |||||||
(unaudited) | ||||||||
Assets | ||||||||
Current assets: | ||||||||
Cash | $ | 36,611,167 | $ | 40,750,133 | ||||
Accounts receivable | 47,976 | 110,141 | ||||||
Prepaid research and development | 565,301 | 107,000 | ||||||
Prepaid expenses and other current assets | 1,165,072 | 1,502,725 | ||||||
Total assets | $ | 38,389,516 | $ | 42,469,999 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 806,196 | $ | 1,089,778 | ||||
Accrued expenses and other current liabilities | 3,574,001 | 2,715,761 | ||||||
Notes payable | — | 248,911 | ||||||
Total liabilities | 4,380,197 | 4,054,450 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, | — | — | ||||||
Common stock, | 25,227 | 25,155 | ||||||
Additional paid-in capital | 68,442,380 | 68,208,081 | ||||||
Accumulated deficit | (34,458,288) | (29,817,687) | ||||||
Total | 34,009,319 | 38,415,549 | ||||||
Total liabilities and stockholders' equity | $ | 38,389,516 | $ | 42,469,999 | ||||
Inhibikase Therapeutics, Inc. | ||||||||
Consolidated Statements of Operations | ||||||||
(Unaudited) | ||||||||
Three Months Ended March 31, | ||||||||
2022 | 2021 | |||||||
Revenue: | ||||||||
Grant revenue | $ | 46,031 | $ | 1,407,165 | ||||
Total revenue | 46,031 | 1,407,165 | ||||||
Costs and expenses: | ||||||||
Research and development | 3,016,991 | 2,431,860 | ||||||
Selling, general and administrative | 1,669,636 | 1,600,576 | ||||||
Total costs and expenses | 4,686,627 | 4,032,436 | ||||||
Loss from operations | (4,640,596) | (2,625,271) | ||||||
Interest expense | (5) | (11,797) | ||||||
Net loss | $ | (4,640,601) | $ | (2,637,068) | ||||
Net loss per share – basic and diluted | $ | (0.18) | $ | (0.26) | ||||
Weighted-average number of common shares – basic and diluted | 25,205,454 | 10,053,949 | ||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-reports-first-quarter-2022-financial-results-and-highlights-recent-period-activity-301548382.html
SOURCE Inhibikase Therapeutics, Inc.
FAQ
What were Inhibikase's earnings results for Q1 2022?
What are the upcoming milestones for Inhibikase in 2022?
What is the cash position of Inhibikase as of March 31, 2022?
